New York, March 28, 2026, 11:13 EDT
Vertex Pharmaceuticals ended Friday down 4.6% at $433.07, reacting to fresh U.S. safety label updates for its flagship cystic fibrosis therapies. Despite the pressure from the label news, BMO Capital’s Evan David Seigerman stood by his outperform call and kept the price target at $600.
That’s especially relevant, since Vertex’s 2026 outlook still points to cystic fibrosis drugs doing most of the heavy lifting. This year’s revenue target lands between $12.95 billion and $13.1 billion, with non-cystic-fibrosis products expected to chip in at least $500 million as the company pushes to ramp up Journavx and Casgevy.
The decline comes even as pipeline updates have been positive. On March 9, Vertex reported late-stage results for its kidney therapy povetacicept, saying it expects to wrap up a U.S. submission by the end of March. Chief Executive Reshma Kewalramani called the data a milestone, saying it “establishes renal medicine as Vertex’s fourth franchise.” Reuters
U.S. prescribing labels for Alyftrek and Trikafta now include reports of serious neuropsychiatric events—think anxiety, depression, sleep issues, suicidal thoughts or behavior—seen in both adults and kids after the drugs hit the market, regardless of any prior psychiatric diagnosis. The updates warn these symptoms can show up as early as the first three months on treatment, urging clinicians to stay alert for new or worsening problems.
Some on the Street aren’t reading the label update as a game-changer. Seigerman at BMO stuck with his outperform and $600 price target on March 27, according to StreetInsider, emphasizing one thing: while the label tweaks could pressure the stock, he doesn’t see much threat to the underlying business.
Earlier this month, Seigerman struck a much more optimistic tone on the kidney front. According to Reuters, he called povetacicept a “clear competitor and potential leader in IgAN”—that’s IgA nephropathy, the kidney disease marked by too much protein in the urine, signaling damage. That puts Vertex squarely up against Otsuka’s Voyxact and Vera Therapeutics’ atacicept. Reuters
But Alyftrek wasn’t supposed to make the cystic fibrosis platform harder to manage—it was designed to shore it up. Back in December, after the FDA gave the green light to the once-daily drug, William Blair’s Myles Minter told Reuters it should help cushion Vertex when Trikafta’s patents run out and sales start to slip.
But there’s a risk on the table. Should the new warnings put a damper on switches to Alyftrek, or push doctors and families to take a step back, Vertex could be forced to rely more on its pipeline. That means extra pressure on the still-ongoing 605-patient povetacicept trial, which needs to deliver two years of data showing it slows kidney-function decline—so far, all it’s shown is a drop in urine protein.
Right now, investors are watching two things: any impact from the label update on cystic fibrosis prescriptions, and whether Vertex manages to get its povetacicept filing in by the March deadline. Shares hit a session low of $431.50 on Friday but finished at $433.07. Volume came in at roughly 1.9 million shares.
